Background {#Sec1}
==========

Increasing interest to treat the underlying cause of cardiac arrest (CA) during resuscitation efforts has evolved since the first extended case series described the use of mechanical chest compressions (MCC) during refractory CA in the coronary catheterization laboratory (cath-lab) 8 years ago \[[@CR1]--[@CR5]\]. This treatment option has led to further studies treating refractory CA in the cath-lab setting \[[@CR6]\]. Treatment with extracorporeal cardio pulmonary resuscitation (ECPR) has further developed this field, but also includes patients who experience CA outside the cath-lab setting, where early experience shows good outcome \[[@CR4]--[@CR7]\]. Some of these studies has been made as case series \[[@CR5]\], ongoing randomized controlled trials (Prague NCT01511666), (Maastricht NCT03101787) (British Columbia NCT02832752) and other organizations have implemented this as a clinical routine \[[@CR6]\]. In our early experience we observed that resuscitation in the cath-lab during simultaneous PCI vastly deviated from the normal ALS-algorithm recommended by guidelines. This demanded adjustments to the ALS-algorithms to be suitable for resuscitation efforts during simultaneous PCI, such as delaying further defibrillation attempts until coronary reperfusion is accomplished. These adjustments were recognized by resuscitation guidelines in 2015 \[[@CR8]\]. The cath lab setting enables monitoring of physiological parameters and thus a more individual patient tailored treatment can be given \[[@CR9]\]. Adequate levels of physiological parameters have previously been correlated with successful return of spontaneous circulation (ROSC) \[[@CR7]--[@CR13]\]. This retrospective analysis therefore explores multiple factors to identify which might be associated with ROSC and survival to understand which patients will do well with MCC alone and which may need ECPR.

Methods {#Sec2}
=======

At the university hospital in Lund Sweden, a tertiary hospital with PCI facilities 24/7, 75 patients suffering CA in the cath-lab have been treated and evaluated in the cath-lab setting from January 1, 2004 to April 9, 2013 where outcome data that has been published \[[@CR1], [@CR5]\]. Detailed information regarding important clinical parameters were collected for 35 patients where, eight patients (23%) suffered CA out of hospital and arrived to the cath-lab with ongoing resuscitation efforts and 27 (77%) suffered CA during the intervention (with approval from the local ethical board in Lund (667/2009)). To evaluate the aspects of important confounding factors related to ROSC and survival, patients were divided into four different groups; data from patients that obtained ROSC were compared to data from those not obtaining ROSC and data for survivors were compared to non- survivors. The following data were collected and compared: Background data including concomitant diseases, reason to be admitted to the cath-lab i.e. the diagnosis, culprit lesion, rhythm causing the CA, drugs used during the resuscitation, anticoagulants used during the intervention, PCI-results, post ROSC-treatment and physiologic data collected during CPR. These data were compared for prediction of ROSC and survival differences.

Statistics {#Sec3}
==========

Background parameters, resuscitation related parameters, PCI treatment variables and post ROSC treatment variables were presented as percentages for categorical data, while mean and standard deviation were used for continuous data, as appropriate. *P*-values for differences between the two groups was calculated using Fisher's exact test for categorical data and using Mann-Whitney U test for numerical parameters. A P-value of \< 0.01 was considered to indicate a significant difference as no other adjustment for multiple comparison was made.

Results {#Sec4}
=======

Eighteen (51%) of the patients gained ROSC and 9 (26%) patients survived with good neurological outcome. There was no difference between those that obtained ROSC and those that did not nor when comparing data from survivors and non-survivors in regards of background data including concomitant diseases, reason for admission to the cath-lab i.e. cardiac diagnosis, culprit lesion, rhythm causing the arrest (Table [1](#Tab1){ref-type="table"}). Both ROSC patients and surviving patients had VF/VT (*N* = 7 (20%)), asystole (*N* = 4 (11%)), bradycardia (N = 7 (20%)) and pulseless electric activity (*N* = 17 (49%)) as the initiating rhythm for CA (Fig. [1](#Fig1){ref-type="fig"}). Fewer ROSC patients and surviving patients received epinephrine and the amount given was lower (Table [1](#Tab1){ref-type="table"}). The CPR time was shorter for those that gained ROSC and survivors (Table [1](#Tab1){ref-type="table"}). Those that arrived at the cath-lab with ongoing CPR had lower chance of obtaining ROSC (22% compared to 53% if the CA occurred in the cath-lab, not significant *P* = 0.086). None of the patients survived when resuscitation was ongoing when they were admitted to the cath-lab (Table [1](#Tab1){ref-type="table"}). There was a significant higher median arterial early diastolic blood pressure among those that obtained ROSC compared to non-ROSC patients (30 (22--40) mmHg vs 19 (14--28) mmHg, *P* = 0.012), but only a trend to higher end diastolic and mean arterial pressures (Table [1](#Tab1){ref-type="table"}), these numerical higher values were also seen among surviving patients however these were not significant (Table [1](#Tab1){ref-type="table"}).Table 1Shows comparison of the data for patients that gained ROSC vs Non-ROSC patients as well for survivor's vs Non-survivorsAllROSCNO ROSCP-valueSurvivorsNon- survivors*P*-value(*N* = 35)(*N* = 18 (51%))(N = 17 (49%))(*N* = 9 (26%))(*N* = 26 (74%))Background data (N (%) or Median (25th - 75th quartile)) Gender (Females)6 (17%)3 (17%)3 (17%)\> 0.991 (3%)5 (19%)\> 0.99 Age (years)72 (61--78)71 (57--75)76 (62--78)0.30674 (55--80)71 (63--78)0.806 AMI10 (29%)6 (33%)4 (24%)0.7115 (56%)5 (19%)0.081 Angina pectoris3 (9%)3 (17%)0 (0%)0.2290 (0%)3 (12%)0.553 Hypertension18 (51%)11 (61%)7 (41%)0.3188 (89%)10 (39%)0.018 Diabetes7 (20%)3 (17%)4 (24%)0.6913 (33%)4 (15%)0.340 Treated hypercholesterolemia6 (17%)3 (17%)3 (18%)\> 0.992 (22%)4 (15%)0.635 Stroke5 (14%)4 (22%)1 (6%)0.3381 (11%)5 (19%)\> 0.99 Heart failure3 (9%)1 (6%)2 (12%)0.6031 (11%)2 (8%)\> 0.99 Asthma2 (6%)0 (0%)2 (12%)0.2290 (0%)2 (8%)\> 0.99 Renal disease2 (6%)1 (6%)1 (6%)\> 0.990 (0%)2 (8%)\> 0.99 Valvular disease2 (6%)0 (0%)2 (11%)0.2990 (0%)2 (8%)\> 0.99 Cancer1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 Smoker7 (20%)4 (22%)3 (18%)\> 0.992 (22%)5 (19%)\> 0.99 X-Smoker9 (26%)5 (28%)4 (24%)\> 0.994 (44%)5 (19%)0.192Reason to be admitted to the Cath-lab (N (%)) Planned Angiography1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Planned PCI1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 N-STEMI4 (11%)3 (17%)1 (6%)0.6032 (22%)2 (8%)0.268 STEMI (all)26 (74%)10 (56%)16 (94%)0.0185 (55%)21 (81%)0.192 Inferior STEMI9 (26%)3 (17%)6 (35%)0.2642 (22%)7 (27%)\> 0.99 Anterior STEMI16 (46%)6 (33%)10 (59%)0.1813 (33%)13 (50%)0.460 Lateral STEMI1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 LBBB1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Acute stent occlusion.1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Tamponade1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 Heart failure1 (3%)1 (6%)0 (0%)\> 0.991 (11%)0 (0%)\> 0.99Culprit lesion (N (%)) 1 vessel26 (74%)12 (67%)14 (82%)0.4335 (55%)22 (85%)0.162 2 vessels7 (20%)4 (22%)3 (18%)\> 0.994 (44%)3 (12%)0.055 Left Main12 (34%)5 (28%)7 (41%)0.4893 (33%)9 (35%)\> 0.99 LAD12 (34%)6 (33%)6 (35%)\> 0.993 (33%)9 (35%)\> 0.99 M2 (6%)2 (11%)0 (0%)0.4892 (22%)0 (0%)0.061 CX4 (11%)2 (11%)2 (12%)\> 0.991 (11%)3 (12%)\> 0.99 RCA7 (6%)1 (0%)6 (12%)0.2291 (0%)6 (8%)\> 0.99 Post lateral1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 LIMA2 (6%)1 (6%)1 (6%)\> 0.991 (11%)1 (4%)0.454Rhythm causing the arrest (N (%)) VF/VT7 (20%)4 (11%)3 (9%)\> 0.992 (6%)5 (14%)\> 0.99 PEA17 (49%)8 (23%)9 (26%)0.5053 (9%)14 (40%)0.460 Asystole4 (11%)3 (9%)1 (3%)0.6032 (6%)2 (6%)0.268 Bradycardia7 (20%)3 (9%)4 (11%)0.6912 (6%)5 (14%)0.268Drugs used during resuscitation efforts (N (%) or Median (25th - 75th quartile)) Epinephrine injection (1 mg)23 (66%)9 (50%)14 (82%)0.0752 (22%)21 (81%)0.003 Dose of Epinephrine1 (0--3)0 (0--1)2 (2--5)0.0040 (0--0.5)2 (1--4)0.008 Nor-Adrenaline24 (69%)11 (61%)13 (76%)0.4714 (11%)20 (77%)0.103 Atropine11 (31%)2 (11%)9 (53%)0.0123 (33%)8 (31%)\> 0.99 Amiodarone1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 Dobutamine11 (31%)6 (33%)5 (29%)\> 0.990 (0%)11 (42%)0.033 Levosimendan1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Isoprenaline1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 Buffer1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 Adenosine1 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99Anti-coagulants during PCI (N (%)) Bivalirudin19 (54%)9 (50%)10 (59%)0.7385 (55%)14 (54%)\> 0.99 Klopidogrel18 (51%)10 (56%)8 (47%)0.7405 (55%)13 (50%)\> 0.99 Prasugrel2 (6%)2 (11%)0 (0%)0.4892 (22%)0 (0%)0.061 Heparin29 (83%)15 (83%)14 (82%)\> 0.998 (89%)21 (81%)\> 0.99 Abciximab3 (9%)2 (11%)1 (6%)\> 0.991 (11%)2 (8%)\> 0.99 ASA21 (60%)11 (61%)10 (56%)0.7336 (67%)15 (58%)0.712 Eptifibatide1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Fondaparinux1 (3%)1 (6%)0 (0%)\> 0.990 (0%)1 (4%)\> 0.99 Ticagrelor4 (11%)1 (6%)3 (18%)0.3380 (0%)4 (15%)0.553 Warfarin3 (9%)2 (11%)1 (6%)0.6581 (11%)2 (8%)\> 0.99PCI results (TIMI flow) (N (%)) 327 (77%)14 (78%)13 (72%)\> 0.997 (78%)20 (77%)\> 0.99 21 (3%)0 (0%)1 (6%)0.4860 (0%)1 (4%)\> 0.99 04 (11%)1 (6%)3 (17%)0.3381 (11%)0 (0%)\> 0.99CPR data (N (%))Median (25th - 75th quartile) CPR prior to arrival13 (37%)4 (22%)9 (53%)0.0860 (0%)13 (50%)0.001 CPR during angiography13 (37%)5 (28%)8 (47%)0.3053 (33%)10 (38%)\> 0.99 CPR during PCI26 (74%)12 (67%)14 (78%)0.4435 (55%)21 (81%)0.192 CPR time in the cath-lab35 (12--52)18 (10--41)50 (33--60)0.00710 (8--25)45 (30--60)0.001Post ROSC treatments (N (%) Median (25th - 75th quartile)) Cooling6 (17%)6 (33%)0 (0%)0.0191 (11%)5 (19%)\> 0.99 Heartmate1 (3%)1 (6%)0 (0%)\> 0.991 (11%)0 (0%)\> 0.99 CABG3 (9%)3 (17%)0 (0%)0.2291 (11%)2 (8%)\> 0.99 Pacing2 (6%)0 (0%)2 (12%)0.2290 (0%)2 (8%)\> 0.99 IABP12 (34%)9 (50%)3 (17%)0.0754 (44%)8 (31%)0.685 Heart transplantation1 (3%)1 (6%)0 (0%)\> 0.991 (11%)0 (0%)\> 0.99Physiologic parameters during CA (Median (25th - 75th quartile)) Arterial Systolic (mmHg)85 (71--103)85 (80--96)84 (48--103)^a^0.59386 (77--98)84 (70--103)^h^0.494 Arterial Early Diastolic (mmHg)24 (18--35)30 (22--40)19 (14--28)^b^0.01234 (23--40)20 (14--30)^i^0.050 Arterial End Diastolic (mmHg)30 (21--44)40 (24--46)26 (18--29)^c^0.07141 (30--43)27 (19--44)^j^0.121 Arterial Mean (mmHg)51 (41--58)53 (48--59)45 (32--58)^d^0.07454 (50--58)46 (37--58)^k^0.270 SpO~2~ (mmHg)81 (74--86)81 (73--82)83 (74--89)^e^0.59977 (76--81)82 (74--87)^l^0.549 ETCO~2~ (mmHg)21 (13--23)21 (16--26)21 (8--23)^f^0.41521 (15--26)21 (13--23)^m^0.653 LSCOt (%)50 (44--56)44 (44--44)53 (45--57)^g^NANA48 (44--56)^n^NA RScot (%)55 (49--58)38 (38--38)58 (55--59) ^g^NANA52 (49--58) ^n^NA AScot (%)54 (48--57)41 (41--41)56 (54--57) ^g^NANA51 (48--57) ^n^NA*AMI* acute myocardial infarction, *PCI* percutaneous coronary intervention, *N-STEMI* non ST-elevation myocardial infarction, *STEMI* ST-elevation myocardial infarction, *LBBB* left bundle branch block, *LAD* left anterior descendent artery, *M* marginal branch, *Cx* circumflex artery, *RCA* right coronary artery, *LIMA* left internal mammary artery, *VF* ventricular fibrillation, *VT* ventricular tachycardia, *PEA* pulseless electrical activity, *SR* sinus rhythm, *ASA* acetyl salicylic acid, *CPR* cardio-pulmonary resuscitation, *CABG* coronary artery by-pass grafting, *IABP* intra aortic balloon counter pulsation,, *SpO*~*2*~ Index finger saturation, *ETCO*~*2*~ end tidal carbon dioxide, *LSctO*~*2*~ left cerebral tissue oximetry, *RSctO*~*2*~ left cerebral tissue oximetry, *ASctO*~*2*~ Average of left and right cerebral tissue oximetry and *NA* Not Applicable^a^(ROSC *N* = 18 and No ROSC *N* = 16), ^b^ (ROSC *N* = 18 and No ROSC *N* = 15), ^c^(ROSC *N* = 18 and No ROSC *N* = 15), ^d^ (ROSC *N* = 14 and No ROSC *N* = 8), ^e^ (ROSC *N* = 18 and No ROSC *N* = 15), ^f^ (ROSC *N* = 7 and No ROSC *N* = 11), ^g^ (ROSC *N* = 1 and No ROSC *N* = 5), ^h^ (Survivors *N* = 9 and Dead *N* = 25), ^i^ (Survivors *N* = 7 and Dead *N* = 24), ^j^ (Survivors N = 7 and Dead N = 15), ^k^ (Survivors *N* = 8 and Dead *N* = 22), ^l^ (Survivors N = 7 and Dead N = 15), ^m^ (Survivors *N* = 4 and Dead N = 15) and ^n^ (Survivors *N* = 0 and Dead *N* = 6)Fig. 1Shows the distribution of rhythm causing the arrest and its relation to ROSC and survival (VF/VT = ventricular fibrillation/ventricular tachycardia, PEA = pulseless electrical activity)

Discussion {#Sec5}
==========

This analysis, although admittedly limited by the small number of patients, shows that it is possible to collect and monitor several important parameters that might be predictors of ROSC and survival during treatment of refractory CA patients in the cath-lab setting. The collected data generated a large amount of information from each patient in aspects of background data, concomitant diseases, cause of the CA, circulatory state, rhythm at the event of CA, type of chest compressions, drugs given during advanced life support (ALS), physiologic parameters during ALS, culprit vessel, PCI-outcome, ROSC and survival. From these data several useful parameters emerged, namely if the patient arrived at the cath-lab with ongoing CPR and the length of time MCC were required in the cath-lab to establish ROSC. Both these clinical factors were associated with ultimately poor outcomes. No patient survived who arrived at the cath-lab with ongoing CPR, while the median time of MCC in the cath-lab for those who did survive was 10 min versus 45 min for those patients not surviving.

Predictive parameters have been previously reported for cardiac arrest. These include co-morbid conditions (concomitant diseases, culprit vessel, circulatory state) that are known to affect outcome for STEMI and following PCI \[[@CR14], [@CR15]\] and the cause of the CA in these specific cases are often known (coronary artery occlusion) but also, parameters important for assessing CPR-quality \[[@CR7], [@CR14]--[@CR16]\], parameters important for the assessment of blood pressure and perfusion that might be useful to predict ROSC and survival \[[@CR10]--[@CR13], [@CR17], [@CR18]\], factors as rhythm at the time of the CA \[[@CR18]\], use of vasoactive drugs \[[@CR19]--[@CR22]\], duration of ALS, TIMI-flow and post-ROSC treatment \[[@CR23]\], are also known factors that can affect outcome after CA and feasible to collect.

In this limited series of cath-lab cardiac arrest, initial rhythm did not predict outcome. One parameter reported in series of ECPR patients that was not included in our database is arterial lactate levels, which has appeared to be markedly different between survivors and non-survivors \[[@CR21]\].

The median cath-lab CPR time among the non-surviving patients (45 min (30--60) in this series, is in the same range as that seen as unfavourable in some ECPR cohort reports. Lamhaut and collaborators showed a significant increase in survival when the decision point for ECPR was set at 20 min of ALS, from the prior 30 min \[[@CR24]\]. This finding of a finite time limit of MCC in the cath-lab of 10 to 20 min to achieve good outcomes suggests that if such a time is approaching the decision for escalating therapy to ECPR must be made before it is too late. Prolonging the period of MCC support too long can impair the chances for a good outcome \[[@CR1]\].

In the present case series, patients with both shockable and non-shockable rhythms achieved long-term survival with MCC (Fig. [1](#Fig1){ref-type="fig"}), whilst most studies using extracorporeal cardio pulmonary resuscitation have been restricted to patients in refractory VF/VT since these CA are assumed to be of a cardiac origin. However, our data shows that this assumption might not be correct and some patients with non-shockable rhythms may also respond to MCC while the cause of their cardiac arrest is treated in the cath lab.

Limitation {#Sec6}
==========

The major limitation is the small number of patients in this case series. Further study with additional patients could better define other important factors regarding the usefulness of MCC in the cath-lab and which patients should go on to ECPR. Another way to overcome this limitation, we suggest collaboration with other cath-labs implementing similar treatment algorithms and monitoring to be able to collect a sufficient number of patients for these rare cases.

Conclusion {#Sec7}
==========

When a cardiac arrest occurring in the cath-lab aortic pressure should be monitored during the resuscitation efforts striving for at least 30 mmHg in diastolic values. If this cannot be achieved escalation of therapy to ECPR should be considered. This decision should be made within the first 10--20 min of resuscitation efforts in the cath-lab, as longer periods are associated with a decrease in survival. Finally, cardiac arrest occurring before and still requiring resuscitation efforts upon arrival at the cath-lab should be considered for ECPR as continuing chest compressions alone resulted in poor outcome.
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:   Advanced life support

CA

:   Cardiac arrest
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:   Cardio- pulmonary resuscitation
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:   Extracorporeal cardio pulmonary resuscitation

MCC

:   Mechanical chest compressions
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:   Coronary catheterization laboratories

ROSC
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:   Thrombolysis in myocardial infarction

VF

:   Ventricular fibrillation
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:   Ventricular tachycardia
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